Downloads: 333

Files in This Item:
File Description SizeFormat 
pin.13007.pdf2.56 MBAdobe PDFView/Open
Title: A case of Langerhans cell sarcoma on the scalp: Whole‐exome sequencing reveals a role of ultraviolet in the pathogenesis
Authors: Katsuragawa, Hiroyuki
Yamada, Yosuke  KAKEN_id  orcid https://orcid.org/0000-0001-7952-2706 (unconfirmed)
Ishida, Yoshihiro
Kaku, Yo
Fujimoto, Masakazu  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-0575-6507 (unconfirmed)
Kataoka, Tatsuki R.
Haga, Hironori  kyouindb  KAKEN_id
Author's alias: 桂川, 広幸
山田, 洋介
石田, 雄大
加来, 洋
藤本, 正数
片岡, 竜貴
羽賀, 博典
Keywords: CDKN2A
Langerhans cell histiocytosis
Langerhans cell sarcoma
MAPK pathway
PD-L1
TP53
ultraviolet
whole-exome sequencing
Issue Date: Nov-2020
Publisher: Wiley-Blackwell
Journal title: Pathology International
Volume: 70
Issue: 11
Start page: 881
End page: 887
Abstract: Langerhans cell sarcoma (LCS) is a high‐grade neoplasm with overtly malignant cytological features and a Langerhans cell phenotype. The underlying genetic features are poorly understood, and only a few alterations, such as those of the MARK pathway‐related genes, CDKN2A and TP53 have been reported. Here we present a 70‐year‐old male with LCS on the scalp and pulmonary metastasis. The multinodular tumor, 3.0 cm in diameter, consisted of diffusely proliferated pleomorphic cells with numerous mitoses (53/10 HPFs). Immunohistochemically, the tumor cells were positive for CD1a, Langerin and PD‐L1, and the Ki‐67 labeling index was 50%. These pathological features were consistent with LCS, and were also observed in the metastatic tumor. Whole‐exome sequencing revealed that both the primary and metastatic tumors harbored a large number of mutations (>20 mutations/megabase), with deletion of CDKN2A and TP53 mutation, and highlighted that the mutational signature was predominantly characteristic of ultraviolet (UV) exposure (W = 0.828). Our results suggest, for the first time, that DNA damage by UV could accumulate in Langerhans cells and play a role in the pathogenesis of LCS. The high mutational burden and PD‐L1 expression in the tumor would provide a rationale for the use of immune checkpoint inhibitors for treatment of unresectable LCS.
Rights: This is the peer reviewed version of the following article: ['Pathology International', 70(11), 881-887], which has been published in final form at https://doi.org/10.1111/pin.13007. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
The full-text file will be made open to the public on 16 August 2021 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/259188
DOI(Published Version): 10.1111/pin.13007
PubMed ID: 33410565
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.